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Subspecies of the African trypanosome, Trypanosoma brucei, which cause human African trypanosomiasis, are transmitted by the
tsetse ﬂy, with transmission-essential lifecycle stages occurring in both the insect vector and human host. During infection of the
human host, the parasite is limited to using glycolysis of host sugar for ATP production. This dependence on glucose breakdown
presents a series of targets for potential therapeutic development, many of which have been explored and validated as therapeutic
targets experimentally. These include enzymes directly involved in glucose metabolism (e.g., the trypanosome hexokinases), as
well as cellular components required for development and maintenance of the essential subcellular compartments that house the
major part of the pathway, the glycosomes.
1.Introduction
African sleeping sickness is considered a “neglected tropical
disease” yet continues to be a major public health risk to
sub-Saharan Africa. A survey from 2005 analyzed by the
World Health Organization indicated that African sleeping
sickness was still prevalent, with an estimated 50,000 to
70,000 cases occurring (http://www.who.int/mediacentre/
factsheets/fs259/en/). A survey from 2009 suggests that the
number of cases is falling, but the current level of disease
management requires stable social conditions for accurate
surveillance and control measures to be eﬀective. Further,
the lack of safe and eﬃcacious treatments emphasizes the
need for research on new therapies. The current drugs used
to treat the disease are often toxic, and their administration
typically requires skilled medical care. Additionally, some of
the compounds fail to function against certain subspecies,
and resistance is a growing concern.
The parasite is transmitted by the bite of the blood-
feeding tsetse ﬂy and initially causes fever, headache, and
joint pain in humans. Winterbottom’s sign, a swelling of
the lymph nodes characteristic of early trypanosome infec-
tion, has long been recognized in association with African
trypanosome infection—slave traders in the 1800s would
relocate their operations within Africa upon its appearance
in populations destined for slavery [1].
As the disease progresses, parasites enter the brain, and
neurological symptoms, such as confusion, disturbed sleep
patterns, extreme lethargy (hence, “sleeping sickness”), and
coma occur. Left untreated, the disease is invariably fatal.
AnnualdeathnumbersasaresultofAfricansleepingsickness
are diﬃcult to determine, as limited monitoring in rural
Africa likely leads to underestimated infection rates.
Human health is also impacted indirectly by the parasite,
as animals used for food are also subject to infection. An
infected animal experiences fever, listlessness, emaciation,
and paralysis, leading the animal to be unﬁt for use,
hence the term “nagana” which is a Zulu word that means
“powerless/useless” [1]. It is estimated that 3 million cattle
die each year from this disease (Food and Agriculture
Organization of the United Nations, http://www.fao.org/).
The prevalence of nagana in animals renders much of the
Africancontinentinhospitableforlivestockproduction,with
an area equal to the continental US unsuitable for beef or
dairy production.
Essential lifecycle stages occur in both the vector and
mammalianhost.Intheﬂymidgut,parasitestakenupduring
a blood meal diﬀerentiate into procyclic form (PF) parasites.2 Molecular Biology International
These parasites escape the peritrophic membrane and invade
the surrounding tissues. Coincident with this behavior, the
parasites diﬀerentiate into an epimastigote form, which
then infects the salivary glands. Once in the salivary
glands, parasites develop into nonproliferative metacyclic
trypanosomes that are competent for establishing infection
in the mammalian host. Delivery of the trypanosome to
the mammal occurs when the ﬂy feeds again. Bloodstream
form (BSF) parasites develop and grow rapidly in the host
blood, with a portion of the population developing into
short stumpy parasites that, when taken up by a feeding ﬂy,
continue the lifecycle.
Lifecycle stages take advantage of distinct niches to fulﬁll
their metabolic needs. PF parasites utilize the abundant
amino acids in their surroundings to generate ATP through
mitochondrial-basedpathways.Whileglycolysisisimportant
to the PF parasites, these parasites can thrive in the absence
of glucose if adapted to low-glucose conditions, indicating
that other metabolic pathways can compensate for the loss of
glycolysis [2, 3].
In BSF parasites, glycolysis of host glucose provides the
sole source of carbon for ATP production. This dependence
on glycolysis for ATP coincides with reduced mitochondrial
function, limiting the metabolic options available to the
parasite and presenting a series of targets for potential
therapeuticdevelopment.Theseincludeenzymesthatpartic-
ipate directly in glycolysis, proteins responsible for enzyme
import into glycosomes, and cellular components involved
in the regulation of glycosome number and diﬀerentiation.
Here, we discuss targeting enzymes of glycolysis, with a
particular focus on the ﬁrst enzyme in the pathway, T. brucei
hexokinase 1 (TbHK1). Additionally, compartmentalization
of the pathway is critical to the success of the parasite, so we
will consider strategies aimed at disruption of mechanisms
the parasite uses during the maturation and development of
glycosomes.
2.Glycolysisinthe BSF AfricanTrypanosome
Metabolism of host glucose through glycolysis is essential
to the success of a BSF parasite mammalian infection, as
the pathway is the sole source of ATP production in the
mammalian infection lifecycle stage. The pathway is orga-
nized into subcellular compartments related to peroxisomes
namedglycosomes.Firstcharacterizedin1977byOpperdoes
and Borst, the single-membrane compartment houses the
ﬁrst seven enzymes of glycolysis [4]. Under aerobic condi-
tions, these enzymes convert glucose to 3-phosphoglycerate,
which is then further metabolized to pyruvate with the
concomitant production of ATP by pyruvate kinase in the
cytosol (Figure 1). The pyruvate is then secreted from the
cell.
One key to the presence of compartmentalized glycolysis
is related to regulation of energy metabolism. ATP and
reducing equivalent depletion and production within the
glycosome are balanced. ATP is consumed by the activity
of the TbHKs and phosphofructokinase (PFK), while it
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Figure 1: Glycolysis and glycosomes in the bloodstream form
African trypanosome. Abbreviations: ALD: aldolase; DHAP:
dihydroxyacetone phosphate; 1,3BPGA: 1,3-bisphosphoglycerate;
ENO: enolase; F-6-P: fructose-6-phosphate; FBP: fructose 1,6-
bisphosphate; G-3-P: glyceraldehyde 3-phosphate; G-6-P: glucose-
6-phosphate;GAPDH:glyceraldehyde-3-phosphatedehydrogenase;
Glc: glucose; Gly-3-p: glycerol-3-phosphate; GPDH: glycerol 3-
phosphate dehydrogenase; Mito: mitochondrial enzymes; PEP:
phosphoenolpyruvate; 2-PGA: 2-phosphoglycerate; 3-PGA: 3-
phosphoglycerate; PGI: glucose-6-phosphate isomerase; PGM:
phosphoglycerate mutase; PFK: phosphofructokinase; PGK: phos-
phoglycerate kinase; PK: pyruvate kinase; PYR: pyruvate; TbHK: T.
brucei hexokinase 1 and/or 2; TPI: triose-phosphate isomerase.
is regenerated by the activity of the glycosomal phospho-
glycerate kinase (gPGK). Additionally, NADH produced by
glyceraldehyde-3-phosphate dehydrogenase is balanced by
NADH oxidation when glycerol 3-phosphate dehydrogenase
(GPDH) metabolizes dihydroxyacetone phosphate (DHAP)
to glycerol 3-phosphate (Gly-3-p). The resulting Gly-3-p
is shuttled from the glycosome to the mitochondria where
electrons are ultimately transferred to water through the
activity of a glycerol 3-phosphate oxidase complex (consist-
ing of a mitochondrial glycerol 3-phosphate dehydrogenase,
ubiquinone, and trypanosomal alternative oxidase). The
shuttle returns DHAP to the glycosome, allowing mainte-
nance of the glycosomal redox balance.
The compartmentalization of a majority of the gly-
colytic pathway segregates important steps in the path
to ATP synthesis and creates what could be considered
additional obstacles to eﬃcient energy metabolism. Why
does the parasite do this? Bakker and colleagues, through a
combination of computational and wet-bench experiments,
have found that compartmentalization of glycolytic enzymes
that lack allosteric regulation prevents the unchecked con-
sumption of ATP in a “turbo-explosion” of glycolysis [5].
That is, because feedback inhibition does not limit TbHK
and PFK activity, these enzymes would generate products
(hexose phosphates) at levels beyond the capacity of the
downstream enzymes if unchecked by compartmentaliza-
tion.Molecular Biology International 3
3. TbHKs as Targets for
Therapeutic Development
In the African trypanosome, TbHK, an activity composed
of an unknown ratio of two proteins (TbHK1 and TbHK2),
mediates the ﬁrst step in glycolysis. Because the enzymes
have the hallmarks of good targets for therapeutic devel-
opment, considerable eﬀort has been directed toward the
development of TbHK inhibitors as potential antiparasitic
compounds. First, both TbHK1 and TbHK2 are essential to
the BSF parasite, as demonstrated by targeted gene silencing
using RNAi constructs speciﬁc to the unique 3  UTRs of
the genes [6, 7]. In both cases, cell toxicity was observed
after3–5 days ofRNAiexposure. Second, chemicalinhibitors
of TbHK1 are toxic to the parasite [7–9]. Third, TbHK1
is likely diﬀerent enough from host enzymes, sharing only
30–33% sequence identity with mammalian HKs, to suggest
that it can be speciﬁcally targeted. Last, TbHK1 has unusual
properties, including oligomerization into hexamers [10]
and is inhibited by compounds distinct from those which
inhibit the mammalian enzymes, including fatty acids, to
suggest that speciﬁc inhibition is possible.
3.1. TbHK1 Inhibitors: Approaches for Discovery. Willson
et al. developed structural-based inhibitors of TbHK that
were antitrypanosomal through modeling of TbHK1 to
known HK structures [9]. These glucosamine derivatives
were tested and found to be competitive with respect to
glucose, with Ki values similar to the KM value for glucose
[9]. However, the compounds were not particularly toxic to
BSF parasites (with LD50s in the range of 5–10mM, and an
LD100 for the best inhibitor of 3.6mM), possibly because the
compounds entered the cell by passive diﬀusion instead of
import against a concentration gradient. Alternatively, the
compounds may have been imported by facilitated transport
through the glucose transporter, again failing to accumulate
to suﬃcient concentrations for toxicity.
TbHK1 inhibitors have also been identiﬁed in surveys
of chemicals that inhibit HKs from other systems. The
activity of molecules identiﬁed by this approach is likely
the result of conserved structural features of mammalian
and trypanosome HKs. For example, the anticancer drug
lonidamine (LND, 1-(2,4-dichlorobenzyl)-1,H-indazol-3-
carboxylic acid), which inhibits human HK and has been
subject to clinical trials in humans also inhibits both
recombinant TbHK1 and TbHKs from parasite lysate and
is toxic to the parasite [7, 11–13]. Additionally, quercetin
(QCN, 3,5,7,3 ,4  pentahydroxyﬂavone), which inhibits a
number of mammalian enzymes including HKs, is toxic to
T. brucei and inhibits recombinant TbHK1 through binding
near the TbHK1 active site [14–16].
Lack of sensitivity of the trypanosome enzymes to other
known HK inhibitors, including glucose-6-phosphate, 5-
thio-D-glucose, and 3-methoxyglucose, suggests that the
TbHKs are suﬃciently unique for therapy development [7].
A group of bisphosphonates that are potent inhibitors of T.
cruzi HK did not inhibit rTbHK1, emphasizing the unique
nature of the TbHKs [17, 18]. Notably, rTbHK2, when
oligomerized in vitro with a catalytically inactive rTbHK1
variant,isactive,andtheactivityissensitivetoPPiinhibition
and, to a lesser extent, the bisphosphonate risedronate [10].
The potential arsenal of leads has recently been expanded
using two screens to identify speciﬁc inhibitors of recom-
binant TbHK1. The ﬁrst screen, of a library of pharmaco-
logically active compounds (LOPAC), yielded 18 primary
hits (>40% inhibition at 10μM) from 1280 compounds,
including myricetin, a bioﬂavonoid that is structurally very
similar to QCN [19]. In addition to the identiﬁcation of
new lead compounds, the LOPAC screen served to validate
the conditions required for automated high-throughput
screening (HTS) of a 220,233 compound library.
The HTS campaign initially yielded 239 compounds
as primary actives (>50% TbHK1 inhibition at 10μM),
which were then cherry-picked and conﬁrmed as TbHK1
inhibitors. Thirteen compounds with IC50 values <50μM
were purchased from commercial sources and ten conﬁrmed
with IC50 values <50μM. Of these ten, six clustered into a
structurally related group (isobenzothiazolinones), and four
were singletons. These compounds had IC50s that ranged
from 0.05–41.7μM, and some of the TbHK1 inhibitors were
toxic to BSF T. brucei,w i t hE C 50 values of 0.03–2.9μM while
not exhibiting toxicity towards mammalian cells [19].
In summary, TbHK1 has served as a viable target for
therapeutic lead development, with the exciting possibility
of the development of potent target-speciﬁc inhibitors
indicated by recent HTS results. These ﬁndings are in
agreement with studies that considered the consequences
of reduced glycolytic ﬂux through inhibition of the TbHKs
on trypanosome growth. Initial in silico studies predicted
that the TbHKs (and several other glycolytic enzymes) were
presentinexcess,suggestingthatsigniﬁcantinhibitionwould
be required to yield a detrimental impact on glycolytic ﬂux
and, therefore, parasite health [20]. However, reﬁnement of
the model combined with additional experimental assess-
ment revealed that TbHK and PYK were less abundant than
initially thought, and that partial inhibition of the enzymes
could suﬃciently reduce ﬂux to toxic levels in the parasite
[6].
3.2. Other Glycolytic Enzymes as Targets. Could other
enzymes in glycolysis be targeted for therapeutic develop-
ment? The other T. brucei H K ,T b H K 2 ,i s9 8 %i d e n t i c a l
to TbHK1, so it is likely that compounds that inhibit
TbHK1 would also impact TbHK2, though the lack of in
vitro HK activity has limited studies into this possibility
[21]. Downstream, other enzymes have limited identity to
human proteins, and several have been validated genetically
or chemically as drug targets (Table 1). For a review of the
potential of other glycolysis enzymes as therapeutic targets,
please see [22, 23].
Mechanisms of regulation of glycolytic enzyme expres-
sion may yield interesting targets. In the case of the TbHKs,
it has been established that (1) either reduced or excessive
expression of TbHK is toxic to the parasite [6, 7], and (2) the
environmentinwhichtheparasiteisgrowninﬂuencesTbHK
expression [10]; however, the molecular mechanisms that
allow precise yet regulable expression remain unresolved.4 Molecular Biology International
Table 1: The T. brucei glycolytic enzymes as potential drug targets.
Enzymea PTS type % identity to human counterpart Status of therapeutic developmentb
TbHK1 PTS2 [24] 38% to HKDC1 CV [7, 9], GV [7, 9],
36% to HXK3
TbHK2 PTS2 [24]G V [ 6, 7]
PGI PTS1 [25] 57% to PGI isoform 2
PFK PTS1 [25] 27 % to PFK, platelet isoform CV [26], GV [6]
ALD PTS2 [26] 4 9 %t ob r a i n( Ci s o z y m e ) C V[ 27], GV [28]
TPI I-PTS [29] 54% to isoform 1 GV [30]
GPDH PTS1 [25, 31] 38% to GPDH2
GAPDH PTS1 [25] 55% to spermatogenic GAPDH-2 CV [32], GV [28]
PGK
PGKA I-PTS [33] 42% to PGK 1
PGKB N/A 43% to PGK 1
PGKC PTS1 [25, 34] 44% to PGK 1 GV [35], CV [36]
PGM N/A 24% to CAMTA1 GV [6]
ENO N/A 63% to ENO2 GV [6]
PK N/A 50% to PKLR
aFor enzyme abbreviations, see Figure 1. CAMTA1: calmodulin binding transcription activator 1; HKDC1: hexokinase domain containing protein 1; HXK3:
hexokinase type 3; N/A: not applicable because the protein is cytosolic; PKLR: pyruvate kinase, liver, and RBC.
bStatus: CV: chemically validated target—inhibitors against the target are toxic to parasites; GV: genetically validated target—genetic manipulation of the
enzyme leads to growth defects or cell death.
4. Glycosomal Glycolytic EnzymeImport:
Targeting the Machinery
Glycosomal resident proteins are encoded by nuclear DNA,
translated on cytosolic polyribosomes and targeted to
glycosomes as a result of bearing a glycosomal targeting
sequence. Proper glycosomal targeting is essential to the
parasite because otherwise glucose is toxic to the parasite.
RNAi of PEX14, a peroxin required for glycosome protein
import, led to accumulation of glycosomal resident proteins
in the cytosolic fraction. This condition was tolerated by PF
parasitesunlesstheywereculturedinthepresenceofglucose.
Ifgrownwithglucose,thePEX14-deﬁcientcellsaccumulated
glucose-6-phosphate, fructose-6-phosphate, and fructose-
1,6-bisphosphate and died [37–39]. Notably, depletion of
TbHK in the PEX14-deﬁcient parasites through simultane-
ous RNAi of the TbHKs and PEX14 yielded cells that were
no longer sensitive to glucose, suggesting that the com-
partmentalization of glycolysis (or the TbHKs) is essential
[38]. Additionally, expression of a targeting-deﬁcient HK
in L. donovani was lethal to parasites in the presence of
glucose [40]. While the observed parasite death may have
resulted from unchecked ATP consumption, the observation
that TbHK1 is regulated by a number of other mechanisms
suggests that this may not be the sole explanation for the
observed glucose toxicity [10, 21].
Three types of targeting sequences are known to mediate
targeting to glycosomes. These sequences, that share simi-
larity with peroxisomal targeting sequences (PTS), include
the PTS1, PTS2, and an I-PTS (internal-PTS). Enzymes
that participate in glycolysis have PTS1, PTS2, and I-PTS
targeting sequences (Table 1).
The PTS1 and PTS2 targeting sequences have been well
characterized while less is known about the I-PTS. PTS1 is a
C-terminalthreeaminoacidsequenceoriginallyidentiﬁedin
ﬁreﬂy luciferase [41]. PTS1-bearing proteins are localized to
peroxisomes (and glycosomes) through an interaction with
the peroxin protein PEX5, with PTS1 recognition occurring
through signal sequence interaction with seven predicted
tetratricopeptide repeats in the PEX5 [42].
The PTS2 was ﬁrst identiﬁed when mutations in the
N-terminus of the rat peroxisomal 3-ketoacyl-CoA thiolase
precursor led to mislocalization of the protein [43]. Mutage-
nesis studies revealed that the N-terminus of Saccharomyces
cerevisiae thiolase (which is identical at 6 of 11 amino acids
with the rat thiolase N-terminus is necessary and suﬃcient
for protein targeting to the peroxisomes [44]. Contrary to
PTS1 and PTS2 signals, the I-PTS sequences lack obvious
similarity, sharing only that they are internally located in a
polypeptide [45].
4.1. PEX7 and PEX5: Central Participants in Glycosome
Targeting. Protein import into the glycosome requires inter-
action with multiple proteins, including those identiﬁed
and characterized for peroxisomal import. For example, S.
cerevisiae PEX7 (originally named PAS7 or PEB1) is involved
in transport of PTS2-bearing proteins to the peroxisome
[46, 47]. The yeast PEX7 does not require a peroxisomal
membrane for binding to the thiolase but binds thiolase in a
PTS2-dependent manner. Further, yeast PEX7 does not need
a free N-terminus near the PTS2 for binding to occur, and
binds thiolase that has already been folded, suggesting that
the protein interacts with thiolase in the cytoplasm and acts
as a shuttle between the cytoplasm and peroxisome [48].Molecular Biology International 5
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Figure 2: PTS binding proteins participate in delivery of glycolytic
enzymes to the glycosome. Fully folded PTS2 harboring proteins
expressed in the cytoplasm, like the TbHKs, are targeted to the
glycosome through the binding of PEX7 to the PTS2. This complex
may or may not interact with PEX5 prior to delivery to PEX14 for
transfer to the glycosome matrix. PFK, which harbors an internal
PTS1 targeting sequence, is targeted by PEX5.
PEX7 homologs have been identiﬁed in three trypanoso-
matid species, T. brucei, L. major,a n dT. cruzi. These PEX7
sequences are 65–76% identical to one another and 32–
36% identical to the human and S. cerevisiae proteins. The
trypanosomatid PEX7s contain a C-terminal proline-rich
∼40 amino acid extension while the equivalent human and
yeast structures have a shorter (5 and 10 residues, resp.)
extension that lacks the proline enrichment.
In mammals, PEX7 bound to PTS2 proteins interacts
with another peroxin, PEX5, for import into peroxisomes
[49, 50]. In 2008, recombinant L. major PEX7 was expressed
and puriﬁed, and this protein was shown to bind to PTS2
sequences [51]. LmPEX7 also binds to a polypeptide derived
from L. donovani PEX5 (LdPEX5). Other trypanosomatids,
including T. brucei and T. cruzi, also harbor a PEX5 homolog
that contains a putative PEX7 binding box located in the
N-terminal half of the protein [52]. These ﬁndings suggest
that the trypanosomatid PEX7 proteins, like the mammalian
PEX7 proteins, function through an interaction with PEX5
protein (Figure 2), though RNAi of PEX5 did not alter
localization of some PTS2 proteins in T. brucei, indicating
this relationship may not be an absolute requirement for all
PTS2 protein import.
T. brucei PEX5 (TbPEX5) is also involved in the import
of PTS1-containing proteins into the glycosome. The PTS1
binding domain of TbPEX5 has been characterized and
consists of tetratricopeptide repeats, which typically form
super helices that allow protein:protein interactions on both
the inner and outer faces [53]. This could allow TbPEX5 to
interact simultaneously with multiple proteins [54].
In summary, glycosomal resident proteins are compart-
mentalized as a result of interactions with peroxins in the
cytoplasm. PEX7 binds PTS2-bearing proteins, followed by
(in some cases) interaction with PEX5, which may also be
loaded with PTS1 harboring proteins. This complex is then
delivered to the glycosomal membrane where it docks with a
glycosomal membrane protein, PEX14, which participates in
import of matrix proteins [38]. The mechanisms of import
of PTS1 and PTS2 proteins are slightly diﬀerent, with PTS1-
targeted proteins translocated into the glycosome coincident
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Figure 3: Proposed overview of glycosome biogenesis and remod-
eling. Proteins without obvious T. brucei homologs are indicated in
italics.
with the release of their PEX5 binding partner back into the
cytoplasm. The PEX7:PTS2 protein complex is translocated
en block into the glycosome where the PTS2 protein partner
is released followed by transport of the PEX7 protein out of
the glycosome [51].
Glycosomal resident matrix proteins are expressed from
cytosolic polyribosomes as fully folded polypeptides [55].
This creates a potentially dangerous situation for the cell,
as inappropriate cytosolic expression of glycolytic enzymes
may be toxic to the parasite [40]. While the mechanisms
that maintain enzymes in an inactive state in the cytosol
are not known, it is tempting to speculate that interaction
with peroxisomal targeting proteins may participate in
preventing cytosolic activity. With that in mind, targeted
disruption of this relationship, through small molecules that
interfere with the protein:protein interactions, for example,
could ablate regulation and prevent appropriate subcellular
localization—with destructive consequences to the parasite.
5. Glycosome Replication and Development as
AdditionalTargets
T. brucei must maintain glycosome number and integrity to
maintainhomeostasisundernormalconditionsandremodel
glycosomal contents during diﬀerentiation and in response
to changes in environmental conditions. Components that
regulate the dynamics of these essential organelles are
potential drug targets.
Glycosome biogenesis involves organelle formation,
import of proteins from the cytoplasm (see above), prolif-
eration, and remodeling (Figure 3). Rapid advances in cell
biology have facilitated the study of peroxisome dynamics in
yeast and other model systems, while less is known about
these processes in T. brucei. Some peroxisome biogenesis
protein gene homologs are readily evident in the T. brucei6 Molecular Biology International
annotated genome while others either lack suﬃcient con-
servation for identiﬁcation or are absent. In some cases,
homology searches may be hampered because the parasites
have streamlined glycosome biogenesis and do not carry out
all of the processes observed in the regulation of peroxisomes
in other systems.
5.1. De Novo Growth of Peroxisomes. Peroxisomes can prolif-
eratethroughdenovobuddingfromtheERand/orbygrowth
andﬁssionofexistingorganelles.Theextenttowhichprocess
predominates is unclear but appears to vary from organism
to organism and is inﬂuenced within a given species by
growth conditions.
In S. cerevisiae, de novo peroxisome formation involves
the integral membrane protein PEX3, which localizes to
the endoplasmic reticulum, forming distinct foci that inter-
act with the peroxisomal membrane protein PEX19. The
PEX3/PEX19 vesicles bud from the ER and mature into
functional peroxisomes [56]. In support of the ER to
peroxisome maturation model, sixteen diﬀerent peroxisomal
membrane proteins were found to localize to the ER in S.
cerevisiae via traditional ER translocation machinery [57]. In
mammalian cells, an additional protein PEX16 (not present
in yeast) is involved in formation of peroxisomes from ER in
the absence of pre-existing organelles [58, 59].
It is unknown if de novo glycosome formation occurs in
T. brucei.Todate,nohomologsforPEX3havebeenidentiﬁed
in T. brucei, although it has been proposed that, through
gene displacement, the parasite has developed an alternative
replacement activity, as the function of this protein in
glycosome biogenesis is likely essential [60].
APEX19homolog,ontheotherhand,hasbeenidentiﬁed
in T. brucei. The protein, TbPEX19, exhibits low sequence
identity (18–22%) to PEX19 from other organisms and was
identiﬁed only when relaxed BLAST searches were employed
[61]. TbPEX19 is essential in T. brucei and is involved in
glycosomal protein import with speciﬁcity that is similar,
though not identical, to that observed for yeast and human
PEX19 [62]. Its role in de novo formation of glycosomes has
not been assessed.
5.2. Growth and Fission of Existing Organelles: The Role
of PEX11 in Early Division. In addition to ER-dependent
formation of peroxisomes, peroxisome proliferation can
also occur through the growth and division of existing
organelles. The early process of elongation and constriction
of peroxisomes involves PEX11 while the later process of
ﬁssion involves a set of dynamin-related proteins (DRPs).
PEX11-familyproteins,theﬁrstproteinstobeimplicated
in peroxisome division, are present in all eukaryotic cells
[63, 64]. All PEX11 homologs are ∼25kDa, with isoelectric
points greater than 9 and signiﬁcant sequence similarities
at their N- and C-termini. The S. cerevisiae PEX11 family
includes PEX11, PEX25, and PEX27 [65]. A. thaliana
contains ﬁve PEX11 isoforms (PEXa-e), while mammals
have three (PEX11 α, β, γ)[ 66–68]. T. brucei PEX11 family
proteins include TbPEX11 as well as two PEX11-like genes,
TbGIM5A and TbGIM5B [69, 70].
In T. brucei, TbPEX11, TbGIM5A, and TbGIM5B are
all associated with the glycosomal membrane via two
transmembrane (TM) domains leaving the N- and C-
termini exposed to the cytoplasm [69, 70]. TbGIM5A and
TbGIM5B are 97% identical with the amino acid diﬀerences
found within the sequence that links the two TM domains
[70]. Like TbPEX11, antiserum that recognizes TbGIM5A
and TbGIM5B cross-reacts with proteins that localize to
glycosomes, and depletion of this protein results in altered
glycosome morphology.
PEX11 proteins undergo a number of posttranslational
changes including dimerization and phosphorylation. In
S. cerevisiae PEX11, homodimers are enriched in mature
peroxisomes, and inhibition of this dimerization results
in the overproliferation of peroxisomes [71]. TbPEX11,
TbGIM5A, and TbGIM5B also form homodimers while
TbGIM5A and TbGIM5B form heterodimers with each
other but do not interact with PEX11 [70]. The functional
signiﬁcance of this interaction in T. brucei is unknown.
S.cerevisiaePEX11isreversiblyphosphorylatedatSer165
and Ser167 [72]. Expressing constitutively dephosphorylated
PEX11 results in cells containing fewer, larger peroxi-
somes while constitutively phosphorylated PEX11 results
in enhanced peroxisome proliferation. There is no experi-
mental evidence that TbPEX11 is phosphorylated in vivo.
Sequence analysis using NetPhos 2.0 (http://www.cbs.dtu
.dk/) predicts ﬁve potential Ser phosphorylation sites (at
residues 42, 50, 154, 159, and 194) and three potential Thr
phosphorylation sites (residues 158, 196, and 197).
In fungi, plants, mammals, and T. brucei, PEX11 reduc-
tion results in cells that contain fewer, larger peroxisomes as
compared to wild-type cells [63, 65, 66, 68, 69]. Likewise,
increased expression results in the production of smaller
peroxisomesingreaterabundancethanfoundinnormalcells
[64–66, 69, 73].
One kinase involved in the phosphorylation of PEX11 is
Pho85,acyclin-dependentkinase.S.cerevisiaestrainslacking
Pho85 had few, larger peroxisomes as compared to parental
yeast while cells overexpressing Pho85 had hyperphospho-
rylated PEX11 [74]. The Pho85 overexpressing yeast also
demonstrated increased rates of peroxisome proliferation in
comparison with wild-type cells, suggesting that Pho85 plays
ar o l ei nr e g u l a t i o no fp e r o x i s o m ep r o l i f e r a t i o n[ 72].
5.3. Growth and Fission of Existing Organelles: The Role of
DRPs in Late Division. Peroxisome ﬁssion is regulated by
a number of dynamin-related proteins (DRPs), which are
large GTPases involved in membrane ﬁssion and fusion. The
peroxisome ﬁssion machinery was ﬁrst identiﬁed through
studies of mitochondrial ﬁssion. In yeast, there are two
DRPs, Vps1 and Dnm1, involved in peroxisome ﬁssion (for
reviews, see [75, 76]). The extent to which each functions
is dependent on the organism as well as growth conditions.
In S. cerevisiae, the Vsp1 dependent system prevails under
conditions in which peroxisome proliferation is repressed
while the Dnm1 pathway predominates when peroxisome
proliferation is induced [77]. T. brucei harbors a single DRP,
TbDLP,althoughitsroleinperoxisomedivisionhasnotbeen
investigated [78, 79].Molecular Biology International 7
DRPs are targeted to the peroxisome membrane through
a series of protein-protein interactions. In yeast, Dnm1 is
targeted to the peroxisome membrane via interaction with
Fis1, a tail anchored protein that has been found to localize
to both the mitochondria and peroxisomes [77, 80, 81]. In
yeast, Dnm1 is bound to Fis1 through the adaptor proteins
Mdv1/Caf4 [80, 82]. In mammals, this adaptor function is
likely performed by another set of proteins as no Mdv1/Caf4
homologs have been identiﬁed. Instead, mammals target
Fis1p to the peroxisome via PEX11β [83]. Vps1 functions
independently of Mdv1/Caf4 and Fis1, being targeted to
peroxisomal membranes via PEX19 [84].
Peptide antibodies generated against residues 12–25 of
TbDLP labeled both mitochondria and glycosomes, though
the glycosomal localization may be an artifact of the highly
distributed mitochondria [78]. Silencing the TbDLP gene
in PF parasites reduced growth rates and resulted in mito-
chondrial abnormalities with little eﬀect on other organelle
morphologies [78]. In another study, silencing TbDLP again
resulted in abnormal mitochondrial morphology with no
obvious eﬀect on glycosome morphology [79]. The lack of
obvious glycosome defects may be a result of the essential
nature of the organelle under these conditions. In standard
procyclic media containing glucose, glycosome defects are
lethal and would not be available for analysis.
5.4. Remodeling of Glycosome Protein Composition: Perox-
isome Speciﬁc Autophagy. Peroxisomes can be selectively
degraded through a conserved mechanism of selective
autophagy termed pexophagy. Microscopic observation of
T. brucei undergoing diﬀerentiation of BSF to PF parasites
revealed a population of glycosomes that associated with
the lysosome. This association is concomitant with changes
in the expression of glycosome proteins and suggests that
this turnover of glycosomes may occur through a process
analogous to pexophagy [85]. Recent bioinformatic analysis
has identiﬁed trypanosome homologs for about one-half of
the known autophagy components from yeast. See [60]f o r
a discussion of the proteins involved in autophagy and their
trypanosome homologs.
5.5. Targeting Glycosome Dynamics with Therapeutics: Chal-
lenges and the Future. Our understanding of T. brucei
glycosome dynamics and biogenesis is limited, particularly
when compared to what is known about the regulation of
peroxisomes from other systems. This is in part due to the
unusual properties of the glycosome—it diﬀers functionally
from peroxisomes in a number of ways that are not limited
to compartmentalization of glycosomes. These diﬀerences
yielda compartmentthatis regulatedby meansdistinct from
peroxisomes—many of the key proteins involved in these
processes lack homologs in other systems. To overcome this
obstacle, one could envision applying the power of forward
genetics, a tool that has been deployed in the study of the
African trypanosome, to identify cellular mechanism that
regulate glycosome dynamics [24]. These genes will include
many parasite-speciﬁc, essential regulators of glycosome
biology—which will add to the list of interesting therapeutic
targets.
6. Conclusions
Glycolysis and mechanisms required for its compartmen-
talization remain attractive targets for therapeutic develop-
ment. Speciﬁc inhibitors of parasite glycolytic enzymes have
been identiﬁed, suggesting that diﬀerences, though they may
be slight, are suﬃcient between mammalian and trypanoso-
mal components for development of novel agents. Pathways
involved in import of glycolytic enzymes into the glycosomes
are being elucidated, and these present interesting targets for
development, given the toxicity of mislocalization of these
activities. Lastly, resolving mechanisms behind the control of
dynamic developmental regulation of glycosomes may yield
additional means of disrupting glucose metabolism in the
cell, a prospect we look forward to tackling.
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